Additive Manufacturing of an Extended-Release Tablet of Tacrolimus

An extended-release tablet of tacrolimus as once-daily dosing was fabricated using 3D printing technology. It was developed by combining two 3D-printing methods in parallel. Indeed, an optimized mixture of PVA, sorbitol, and magnesium stearate as a shell compartment was printed through a hot-melt extrusion (HME) nozzle while an HPMC gel mixture of the drug in the core compartment was printed by a pressure-assisted micro-syringe (PAM). A 3D-printed tablet with an infill of 90% was selected as an optimized formula upon the desired dissolution profile, releasing 86% of the drug at 12 h, similar to the commercial one. The weight variation, friability, hardness, assay, and content uniformity determination met USP requirements. A microbial evaluation showed that the 3D-printed tablet does not support microbial growth. SEM analysis showed smooth surfaces with multiple deposited layers. No peak interference appeared based on FTIR analysis. No decomposition of the polymer and drug was observed in the printing temperature, and no change in tacrolimus crystallinity was detected based on TGA and DSC analyses, respectively. The novel, sTable 3D-printed tablet, fabricated using controllable additive manufacturing, can quickly provide tailored dosing with specific kinetic release for personalized medicine at the point-of-care.

Automated summary

An extended-release tablet of tacrolimus as once-daily dosing was fabricated using 3D printing technology. The tablet was developed by combining two 3D-printing methods and met the USP requirements for weight variation, friability, hardness, assay, and content uniformity. SEM analysis showed smooth surfaces with multiple deposited layers, and there was no decomposition of the polymer and drug observed at the printing temperature. The novel 3D-printed tablet with tailored dosing and specific kinetic release has the potential to be used for personalized medicine.